Centrophenoxine for Health & Longevity

Evidence Review created on 05/03/2026 using AI4L / Opus 4.7

Also known as: Meclofenoxate, Lucidril, Meclofenoxate Hydrochloride, Centrophenoxin, Helfergin, Cerutil, ANP 235, Analux, Brenal

Motivation

Centrophenoxine (also called meclofenoxate or, by its original brand name, Lucidril) is a synthetic compound created in late-1950s France that delivers a choline-like molecule into the brain. It has drawn long-standing interest in the longevity community as one of the few candidates linked to clearance of an age-related cellular waste pigment that builds up inside aging neurons and other long-lived cells, alongside historical reports of lifespan extension in laboratory mice.

For more than half a century, centrophenoxine has been prescribed in parts of Europe and Asia for cognitive decline, head-trauma sequelae, and certain pediatric and toxicology indications, while remaining an unapproved drug in the United States that nevertheless circulates broadly as a “nootropic” supplement. The most cited human trial is small, and clinical data are best described as suggestive rather than convincing, sitting awkwardly beside a much larger and older preclinical literature on aging brain tissue.

This review examines the evidence on centrophenoxine’s mechanisms, expected benefits, risks, interactions, and practical considerations as a longevity-oriented intervention.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Meclofenoxate

Encyclopedic overview covering centrophenoxine’s chemical synthesis from DMAE and 4-chlorophenoxyacetic acid, its clinical use in conditions from age-related cognitive decline to vertigo and pediatric enuresis, the lifespan-extension data in mice, the international regulatory patchwork (Japan, China, parts of Europe versus the United States), the WADA in-competition prohibition, and the typical dose range of 500–2,000 mg daily.

Examine

Centrophenoxine

Examine’s supplement page describes centrophenoxine as a cholinergic compound carrying a DMAE moiety into the brain more efficiently than DMAE alone, summarizing the human and animal data on cognition in the elderly and on lipofuscin clearance, with referenced citations to the underlying primary literature.

ConsumerLab

No dedicated ConsumerLab page for centrophenoxine or meclofenoxate was found. ConsumerLab does not typically test unapproved drug ingredients sold as nootropic supplements, especially those listed as prohibited substances in sport.

Systematic Reviews

A selection of the most relevant systematic reviews and meta-analyses examining centrophenoxine’s effects across key health domains.

Cholinergic medication for antipsychotic-induced tardive dyskinesia - Tammenmaa-Aho et al., 2018

Cochrane systematic review and meta-analysis of 14 trials of cholinergic drugs (including meclofenoxate) versus placebo in antipsychotic-induced TD (tardive dyskinesia, an involuntary movement disorder). The pooled evidence is rated very low to low quality and shows no clear benefit of older cholinergic drugs.
Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials - Tammenmaa et al., 2004

Meta-analysis of 11 randomized controlled trials (261 patients) of cholinergic agents — including meclofenoxate — for neuroleptic-induced tardive dyskinesia, finding only a non-significant trend toward improvement and no evidence supporting administration of meclofenoxate, lecithin, or deanol in this indication.
Treatment of urinary incontinence after stroke in adults - Thomas et al., 2008

Cochrane systematic review of 12 trials of post-stroke urinary incontinence interventions, with a sub-analysis of one trial of meclofenoxate that reported fewer urinary symptoms in the active group than in controls, while flagging that overall trial quality was insufficient to guide care.

Mechanism of Action

Centrophenoxine is the ester of DMAE (dimethylaminoethanol, a choline-like amine) and 4-chlorophenoxyacetic acid (pCPA, a synthetic plant auxin). After oral absorption it is hydrolyzed by serum and tissue esterases into its two parent moieties; its in vivo activity is best understood as enhanced delivery of DMAE to the brain plus the independent effects of DMAE itself.

DMAE delivery and acetylcholine support: DMAE is structurally related to choline (choline minus one methyl group). Free DMAE crosses the blood-brain barrier poorly. Esterification with the lipophilic chlorophenoxyacetic acid moiety increases brain penetration, raising central DMAE levels. Within neurons, DMAE may be N-methylated to choline and then incorporated into acetylcholine via choline acetyltransferase, modestly supporting cholinergic neurotransmission. DMAE may additionally inhibit peripheral choline uptake, sparing more circulating choline for the central nervous system.
Membrane phospholipid maintenance: DMAE is an intermediate in the Bremer pathway of phosphatidylcholine synthesis. Centrophenoxine increases neuronal incorporation of DMAE-derived lipids into membrane phospholipids, a mechanism repeatedly invoked to explain its membrane-stabilizing effects in aged neurons.
Lipofuscin reduction: Centrophenoxine’s most distinctive preclinical signal is reduction of lipofuscin (an autofluorescent age pigment composed of cross-linked, oxidized lipids and proteins that accumulates in the lysosomes of post-mitotic cells). In aged guinea-pig, rat, and mouse neurons, repeated dosing reduces lipofuscin granule density in the cortex, hippocampus, and other brain regions; not all studies (e.g., rhesus monkey retinal pigment epithelium, the pigmented cell layer at the back of the eye) have replicated this effect, and a 1983 Fischer rat study (Katz & Robison) found no reduction in retinal or frontal-cortex lipofuscin after 11 weeks of injections.
Antioxidant and free-radical scavenging actions: Centrophenoxine increases the activity of catalase and superoxide dismutase (SOD, an antioxidant enzyme that disposes of superoxide radicals) in aged rat brain, reduces lipid peroxidation (e.g., MDA (malondialdehyde, a marker of oxidative lipid damage) levels), preserves glutathione (GSH, the principal intracellular antioxidant tripeptide), and reduces nitric-oxide-related oxidative stress in rotenone (a pesticide used to model Parkinson’s-like dopaminergic neurodegeneration in rodents) models of Parkinson’s disease.
Cerebral metabolism and blood flow: Animal data and older clinical reports describe modest increases in cerebral glucose uptake, oxygen utilization, and regional blood flow, mechanisms that have been used to justify use after stroke or head trauma in some jurisdictions.
α-Synuclein modulation (preclinical): In recombinant α-synuclein systems, meclofenoxate distorts the protein’s conformation and reduces formation of aggregation-competent oligomers in a concentration-dependent fashion, providing a candidate mechanism for the dopaminergic preservation seen in animal Parkinson’s models.
Transcriptomic effects in aging brain: In an annual killifish brain RNA-seq study, lifelong meclofenoxate exposure partially reversed age-associated downregulation of synaptic and neuronal-activity genes, while leaving age-related upregulation of inflammatory genes largely unaffected and increasing expression of certain senescence-associated transcripts.

Pharmacological properties. Centrophenoxine is a small (molar mass 257.7 g/mol), lipophilic ester. After oral dosing, it is rapidly hydrolyzed in the liver and serum to DMAE and 4-chlorophenoxyacetic acid; intact centrophenoxine is essentially undetectable systemically and clinical pharmacokinetics are described in terms of its metabolites. Reported serum half-lives in humans are short and variable, with most sources citing 4–6 hours for the DMAE-related pharmacodynamic effect, supporting twice-daily dosing. DMAE itself has a longer apparent half-life (in excess of 24 hours by some pharmacokinetic estimates). Selectivity is broad rather than receptor-specific: centrophenoxine acts via several pathways (cholinergic, antioxidant, membrane-phospholipid) rather than a single target. Tissue distribution favors highly perfused organs and the brain after blood-brain-barrier passage. Metabolism is primarily by non-CYP esterases; centrophenoxine is not a meaningful substrate of major cytochrome P450 enzymes such as CYP3A4 (a major liver enzyme that metabolizes many drugs), so most pharmacokinetic drug interactions arise from the DMAE moiety and from pharmacodynamic overlap with cholinergic and stimulant agents rather than from CYP inhibition or induction.

Historical Context & Evolution

Centrophenoxine was synthesized in 1959 at the French pharmaceutical laboratory Centre Européen de Recherches Mauvernay (the source of the “Centro-“ name) and was launched as Lucidril for senile cognitive complaints, head injury, and neurological recovery. Through the 1960s and 1970s it was registered as a prescription medicine in France, Germany, Hungary, Austria, Italy, the Soviet Union, Japan, and several other markets, with overlapping indications spanning age-related cognitive decline, post-stroke and post-traumatic brain syndromes, alcohol-related cognitive impairment, vertigo, and (in some jurisdictions) pediatric nocturnal enuresis.

Two distinct research streams emerged in parallel. Geriatric psychiatry trials, mostly small and conducted in continental Europe between the 1960s and the 1990s, evaluated meclofenoxate in mild-to-moderate dementia and produced mixed but generally favorable signals on memory, attention, and overall psychogeriatric scales. The most-cited single study is Marcer & Hopkins’s 1977 placebo-controlled trial in healthy elderly volunteers, which reported a significant benefit on delayed free recall but no effect on five other memory measures. Romanian work led by D. and S. Riga in the 1980s–2000s pooled meclofenoxate against piracetam, pyritinol, nicergoline, and an in-house combination called Antagonic-Stress, ultimately positioning the combination — for which the same authors hold patents — as superior, a finding that should be read in the context of that direct conflict of interest.

In parallel, a biogerontology stream beginning with Karoly Nandy’s guinea-pig and rat studies in the late 1960s, and including a 1973 mouse study by Hochschild reporting an approximately 26.5% increase in mean lifespan, established centrophenoxine as the prototype “anti-lipofuscin” intervention. These animal data were popularized in the longevity literature of the 1980s–2000s by the Riga group and by life-extension publications such as Life Extension Magazine. Subsequent work (e.g., the 1983 Katz & Robison Fischer-rat study and a 1986 rhesus-monkey RPE (retinal pigment epithelium) study) failed to replicate the lipofuscin reduction in some species and tissues, complicating the simple “lipofuscin scrubber” narrative.

The U.S. trajectory has been markedly different. The Food and Drug Administration has never approved centrophenoxine for any indication, and the modern story has been dominated first by its rebranding as a “nootropic” dietary supplement and then by regulatory pushback: the 2022 Cohen et al. analysis showed only one of seven over-the-counter products contained a label-accurate dose, and the World Anti-Doping Agency now lists meclofenoxate as a prohibited in-competition stimulant. Recent preclinical work has shifted toward Parkinson’s disease (anti-aggregation effects on α-synuclein, dopamine preservation in rotenone models) and integrative-omics aging studies, while large, modern, well-controlled human trials remain absent.

Expected Benefits

High 🟩 🟩 🟩

There are no benefits supported by high-quality, replicated, modern human evidence at this level for centrophenoxine.

Medium 🟩 🟩

Memory in Healthy Older Adults

The most-cited human trial — Marcer & Hopkins’s 1977 double-blind, placebo-controlled study in 74 healthy elderly volunteers — found that 9 months of centrophenoxine 1,200 mg/day produced a statistically significant improvement on delayed free recall (a measure of consolidation of new information into long-term memory), but no effect on the other five memory measures tested. Several smaller European trials in mild-to-moderate dementia using meclofenoxate as monotherapy or comparator reported improvements in psychogeriatric scales and Wechsler memory and intelligence subscales, although these studies are small, dated, and methodologically weak by modern standards. Animal models in aged rats consistently show improvements in maze learning, passive avoidance, and hippocampal CA3 firing patterns when meclofenoxate is given to older but not younger animals.

Magnitude: A single positive memory subscale (delayed free recall) of six tested in the largest double-blind placebo-controlled trial (n = 74); psychogeriatric scale improvements in small comparative dementia trials of typically 20–60 patients per arm, without confirmation in modern adequately powered trials.

Lipofuscin Reduction in Aged Brain Tissue ⚠️ Conflicted

Multiple aged-rodent studies in the 1960s–1990s, beginning with Nandy’s guinea-pig work, report reductions in lipofuscin granule density and autofluorescence in the cortex, hippocampus, and brainstem of old animals after weeks-to-months of meclofenoxate treatment, paralleled by reductions in lipid peroxidation and partial restoration of multiple-unit hippocampal activity. Lipofuscin is a hallmark age pigment composed of oxidized, cross-linked lipid–protein residues, and its reduction is mechanistically plausible given centrophenoxine’s antioxidant and lysosome-related effects. Replication is incomplete: a 1983 Fischer-rat study and a 1986 rhesus-monkey study found no reduction in retinal or frontal-cortex lipofuscin, and no human study has directly measured lipofuscin in living tissue.

Magnitude: Reductions on the order of 30–50% in stained lipofuscin area or fluorescence intensity in positive aged-rodent studies; null in some rodent and primate studies; not measured in humans.

Low 🟩

Antioxidant Marker Improvement in Aging Models

Aged-rat studies report that chronic meclofenoxate increases brain catalase and SOD activity, reduces MDA and other lipid-peroxidation products, and preserves GSH levels. In a rotenone model of Parkinson’s disease, centrophenoxine attenuated dopamine depletion, reduced GSH loss, and lowered nitric oxide and citrulline elevations in the midbrain. These mechanistic signals are consistent with antioxidant activity but have not been confirmed by changes in clinical antioxidant or oxidative-stress biomarkers in adequately controlled human studies.

Magnitude: Not quantified in available human studies; preclinical effects are typically in the range of 20–60% modulation of brain antioxidant enzyme activity and oxidative-damage markers.

Cognitive Recovery After Acute Brain Insults

Older European clinical experience and small trials describe symptomatic improvement after meclofenoxate in patients with post-stroke cognitive impairment, traumatic brain injury, alcohol-related encephalopathy, and hepatic encephalopathy (a reversible decline in brain function caused by liver failure that allows neurotoxins such as ammonia to reach the brain; an ongoing trial pairs meclofenoxate with coenzyme Q10 in this last indication). The evidence base is heterogeneous, mostly pre-1990, and limited by small sample sizes and inconsistent endpoints; modern meta-analyses do not exist for these indications.

Magnitude: Not quantified in available studies.

Lifespan Extension in Mice ⚠️ Conflicted

A 1973 Hochschild mouse study and several Riga-group reports describe maximum-lifespan increases of around 26–40% in male Swiss Webster and other mouse strains given chronic meclofenoxate. The effect has not been independently replicated in modern, properly randomized, adequately powered rodent lifespan programs (e.g., the National Institute on Aging Interventions Testing Program has not published a positive centrophenoxine lifespan trial), and the available papers predate modern reporting standards. The signal is interesting but should be regarded as preliminary at the preclinical level.

Magnitude: 26.5% mean lifespan increase reported in the Hochschild Swiss Webster male-mouse cohort; up to ~40% in some Riga-group reports; not replicated in modern controlled rodent aging programs.

Speculative 🟨

α-Synuclein Anti-Aggregation and Parkinson’s-Relevant Effects

In vitro work shows that meclofenoxate distorts the native conformation of α-synuclein and reduces the formation of aggregation-prone oligomers in a concentration-dependent way, and rodent rotenone models of Parkinson’s disease show preserved dopamine and motor function with centrophenoxine co-treatment. These signals are preclinical only; no clinical trial has tested centrophenoxine in Parkinson’s disease.

Senescence- and Choline-Pathway Modulation in Aging Brain

Annual-killifish RNA-seq work shows that lifelong meclofenoxate reverses some age-associated declines in neuronal activity gene expression while not preventing age-related inflammatory upregulation, and chemical-genetic screens have identified centrophenoxine as a chemical compensator in yeast and animal models of mitochondrial phospholipid depletion linked to Parkinson’s disease. These findings are exploratory and not directly translatable to human longevity outcomes.

Skin and Cosmetic Effects

Topical DMAE (the in vivo metabolite of centrophenoxine) has a small literature describing short-term firming effects on facial skin, occasionally extrapolated to oral centrophenoxine. No controlled human study has tested oral centrophenoxine on skin endpoints, and any such effect would need to be inferred from DMAE pharmacology rather than centrophenoxine specifically.

Benefit-Modifying Factors

Age: Multiple aged-rodent studies (e.g., Sharma 1993) found no effect of centrophenoxine on hippocampal activity, lipid peroxidation, or lipofuscin in young (4–8 month) animals, with effects emerging only in older (16–24 month) animals; the strongest human signal also comes from elderly cohorts. The intervention appears to be biologically more meaningful at older ages.
Baseline cognitive status: Effects in mild-to-moderate Alzheimer-type and vascular dementia trials are larger, on group-level scales, than in healthy older adults, where most outcomes are unchanged. Baseline lipofuscin burden, choline status, and cholinergic-system integrity are plausible modifiers but have not been measured in human trials.
Choline and B-vitamin status: Because centrophenoxine’s cholinergic effect depends on conversion of DMAE to choline and acetylcholine, low dietary choline, vitamin B6, B12, or folate status (cofactors for one-carbon metabolism and methylation) may blunt response; conversely, a choline-rich diet provides much of the same upstream substrate without the DMAE pathway.
Sex: Most positive mouse lifespan and aging-rodent data come from male animals; the killifish brain transcriptome study found that the gene-expression effect of meclofenoxate was more pronounced in females. Direct sex-stratified human cognitive data are not available.
Genetic polymorphisms: Variants in PEMT (phosphatidylethanolamine N-methyltransferase, an enzyme synthesizing phosphatidylcholine), CHKA (choline kinase alpha), MTHFR (methylenetetrahydrofolate reductase, an enzyme central to one-carbon metabolism), and APOE (apolipoprotein E, the strongest common genetic risk factor for late-onset Alzheimer’s) plausibly modify response, particularly given centrophenoxine’s involvement in choline–phospholipid metabolism. None of these have been tested in dedicated trials.
Pre-existing health conditions: Active depression, bipolar disorder, schizophrenia, or seizure disorder may attenuate apparent benefit and increase risk; uncontrolled hypertension and Parkinson’s disease may alter both response and safety profile.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Mild Stimulant-Type Adverse Events (Insomnia, Restlessness, Headache, Dizziness)

Across European clinical experience, cognitive-vitality summaries, and the small trial literature, the most consistently reported adverse events are mild stimulant-like effects: insomnia, restlessness, irritability, headache, dizziness, and gastrointestinal upset. These are described as dose-dependent and typically resolve after dose reduction or discontinuation. They are the dominant tolerability signal at typical supplemental doses (500–2,000 mg/day).

Magnitude: Frequently reported across small clinical cohorts and case series; quantitative incidence rates are not reliably estimated due to the small, heterogeneous trial base.

Medium 🟥 🟥

A randomized controlled trial of DMAE (the active in vivo metabolite of centrophenoxine) in 242 patients with mild cognitive impairment reported 3 serious adverse events — fatal cardiac failure, cardiac arrest, and seizure — that the investigators could not exclude as related to study drug. While these events occurred with isolated DMAE rather than centrophenoxine itself, centrophenoxine generates DMAE in vivo, and the pharmacology is shared. The Alzheimer’s Drug Discovery Foundation explicitly raises this as a safety consideration for centrophenoxine.

Magnitude: 3 serious adverse events potentially related to study drug among 242 DMAE-treated patients in a single trial; rate not separately characterized for centrophenoxine.

Mood and Psychiatric Effects

Reports across the centrophenoxine and DMAE literatures include occasional depression, anxiety, agitation, and mood lability, with isolated reports of muscle tension and tremor that resemble cholinergic over-activity. Patients with bipolar disorder, schizophrenia, or other primary psychiatric illness may be particularly susceptible.

Magnitude: Not quantified in available studies; reported as occasional rather than common.

Product-Quality and Mislabeling Risk

A 2022 Clinical Toxicology analysis of 7 over-the-counter centrophenoxine “dietary supplements” sold in the United States found that all contained centrophenoxine (an unapproved drug), but only 1 of 7 (14%) was within ±10% of the label-claimed dose, with daily intakes of 237–752 mg per the maximum recommended serving. Consumers therefore face a substantial risk of unintentional under- or overdosing, plus the regulatory risk of using an unapproved drug, simply by trusting label values.

Magnitude: 6 of 7 (86%) U.S. supplements off-label by more than ±10%; daily exposures of 237–752 mg at recommended servings.

Low 🟥

Hypertension and Cardiovascular Risk in Susceptible Individuals

Older clinical references caution against use in patients with severe hypertension or significant arrhythmia, citing the stimulant-type pharmacology and the cardiac signals from DMAE trials. Most modern source material reiterates this caution despite a sparse formal evidence base.

Magnitude: Not quantified in available studies.

Seizure Threshold Lowering

The DMAE trial in mild cognitive impairment reported a seizure as a serious adverse event, and meclofenoxate is generally not recommended in active epilepsy. A clear human dose-response for this risk is not established.

Magnitude: Not quantified in available studies.

Speculative 🟨

Reproductive and Developmental Toxicity

In preclinical studies, DMAE has produced neural-tube defects in mouse embryos cultured in vitro, with embryos showing impaired conversion of choline to phosphatidylcholine. On this basis, secondary sources advise that women of child-bearing potential, and especially pregnant or breastfeeding women, avoid centrophenoxine. Direct human reproductive data do not exist.

Long-Term Safety in Healthy Adults

Centrophenoxine has been used clinically for more than 60 years, but most exposure data come from short-to-medium-term courses (weeks to several months) in older patients. There are essentially no controlled long-term safety data in healthy younger adults using it as a daily nootropic, and the long-term effect on cellular senescence-related gene expression is mixed in the limited transcriptome work available.

Doping and Regulatory Sanction

Meclofenoxate is on the WADA Prohibited List as an in-competition stimulant. Athletes subject to anti-doping rules face a sport-specific risk independent of the medical risk profile, including via inadvertent contamination of nootropic stacks.

Risk-Modifying Factors

Genetic polymorphisms: Variants in PEMT, CHKA, MTHFR, and BHMT (betaine-homocysteine methyltransferase) plausibly modify DMAE-derived choline and methylation handling; APOE4 (the ε4 allele of apolipoprotein E, the strongest common genetic risk factor for late-onset Alzheimer’s disease) carriers and individuals with familial long-QT or other arrhythmia genotypes may have greater theoretical susceptibility to the cardiac signals seen with DMAE.
Baseline biomarker levels: Elevated baseline blood pressure, abnormal QTc (corrected QT interval, a heart-rate–adjusted ECG (electrocardiogram) measure of ventricular repolarization) intervals, low choline or B-vitamin status, and active liver or kidney impairment may all alter risk; none are formally characterized in centrophenoxine trials, but they are routinely flagged by clinical references as worth screening.
Sex: Reproductive risk concerns apply specifically to women of child-bearing potential because of the in-vitro DMAE neural-tube-defect signal. Sex-specific risk data on cardiac and psychiatric outcomes are not available.
Pre-existing health conditions: Severe hypertension, untreated arrhythmia, recent acute coronary syndrome, active epilepsy, bipolar disorder, schizophrenia, severe hepatic or renal impairment, and pregnancy or breastfeeding are the most commonly cited contraindications or relative contraindications.
Age: Adverse-event sensitivity rises with age and polypharmacy; older adults are also the population in which most efficacy data exist, so the same age range carries both highest plausible benefit and highest baseline risk.

Key Interactions & Contraindications

Cholinergic and acetylcholinesterase-inhibitor drugs (donepezil, rivastigmine, galantamine, pyridostigmine): Additive cholinergic effects (nausea, bradycardia, increased gastrointestinal motility, bronchospasm). Severity: caution. Mitigation: avoid combination outside a supervised dementia treatment plan; monitor for cholinergic toxicity if combined.
Anticholinergic agents (oxybutynin, scopolamine, first-generation antihistamines such as diphenhydramine, tricyclic antidepressants): Pharmacodynamic antagonism may blunt the intended cognitive effect of centrophenoxine, while sparing the stimulant component. Severity: monitor.
Stimulants (amphetamines, methylphenidate, modafinil, high-dose caffeine, ephedrine-type sympathomimetics): Additive central stimulation, insomnia, hypertension, anxiety. Severity: caution. Mitigation: avoid combining stimulants late in the day; reduce centrophenoxine dose if combined.
Antihypertensives (ACE inhibitors such as ramipril, ARBs (angiotensin II receptor blockers, e.g., losartan, valsartan), beta-blockers, calcium channel blockers): Theoretical antagonism of blood-pressure control because of centrophenoxine’s stimulant-type pharmacology. Severity: monitor blood pressure when starting or titrating.
MAOIs (monoamine oxidase inhibitors such as phenelzine, tranylcypromine, selegiline) and serotonergic agents (SSRIs such as sertraline, fluoxetine): Theoretical risk of additive autonomic and pressor effects with MAOIs; additive insomnia or agitation with serotonergic antidepressants. Severity: caution.
Antiepileptic drugs (levetiracetam, lamotrigine, valproate, carbamazepine): Centrophenoxine’s seizure-threshold concern may complicate seizure control. Severity: avoid in active epilepsy unless under specialist supervision.
Anticoagulants and antiplatelets (warfarin, direct oral anticoagulants such as apixaban or rivaroxaban, aspirin, clopidogrel): No specific PK interaction is documented, but underlying hypertension and stimulant effects may increase the consequences of any bleeding event in anticoagulated patients. Severity: monitor.
Other nootropics (piracetam, oxiracetam, aniracetam, alpha-GPC, citicoline, huperzine A): Frequently stacked with centrophenoxine in nootropic communities; cumulative cholinergic burden may produce headache, nausea, and irritability when alpha-GPC, citicoline, or huperzine A is added. Severity: caution; lower one component if symptoms emerge.
Alcohol: Although centrophenoxine has historically been used in alcohol-related encephalopathy, acute heavy alcohol intake compounds blood-pressure variability and sleep disruption and is best avoided around dosing.
Populations who should avoid centrophenoxine: women who are pregnant, breastfeeding, or actively planning pregnancy; people with active epilepsy or a history of seizure disorder; people with severe or uncontrolled hypertension (systolic > 180 mmHg or diastolic > 110 mmHg); those with a recent (<3 months) acute coronary syndrome, decompensated heart failure (NYHA (New York Heart Association, a four-tier functional classification of heart failure severity) Class III–IV), or significant unmanaged arrhythmia (e.g., long-QT syndrome, QTc > 500 ms); people with significant hepatic impairment (Child-Pugh Class B or C) or stage 4–5 chronic kidney disease (eGFR < 30 mL/min/1.73 m²); athletes subject to in-competition WADA testing; and any individual with active bipolar disorder or schizophrenia not under specialist psychiatric care.

Risk Mitigation Strategies

Confirmed contraindication screen before use: before any first dose, screen for pregnancy, planned pregnancy, breastfeeding, active epilepsy or seizure history, severe or uncontrolled hypertension (systolic ≥ 180 mmHg or diastolic ≥ 110 mmHg), recent (<3 months) acute coronary syndrome or decompensated heart failure, significant arrhythmia (e.g., QTc > 500 ms), Child-Pugh Class B or C liver disease, eGFR < 30 mL/min/1.73 m², bipolar disorder, schizophrenia, and competitive sport with WADA testing — to prevent the cardiac, neurological, reproductive, and regulatory risks identified above.
Low starting dose with slow titration: begin at 250 mg once daily with the morning meal for 3–7 days, then increase to 250 mg twice daily, escalating by 250 mg every 1–2 weeks if needed up to a maximum of 1,000 mg twice daily — to minimize stimulant-type adverse events (insomnia, restlessness, headache) and to detect blood-pressure or arrhythmic intolerance early.
Avoid late-day dosing: take the last dose no later than early afternoon (target 14:00 local time) — to prevent insomnia and sleep fragmentation, which is the most consistently reported tolerability issue.
Monitor blood pressure and heart rate at baseline and during titration: measure resting blood pressure and pulse before starting, again at 1–2 weeks, and any time the dose is increased — to detect the cardiovascular signal associated with the DMAE moiety before it becomes clinically significant.
Choose a verified-quality product and confirm the actual content: prefer centrophenoxine raw material that comes with a current Certificate of Analysis, third-party HPLC (high-performance liquid chromatography) verification, and an identified manufacturer; given that 6 of 7 U.S. retail products were off-label by more than ±10% in 2022 testing, this directly mitigates underdosing, overdosing, and adulterant exposure.
Avoid combination with other strong cholinergics or stimulants when starting: during the first 4 weeks, do not co-administer alpha-GPC, citicoline, huperzine A, modafinil, or high-dose caffeine — to reduce the risk of additive cholinergic or stimulant adverse events while the individual response profile is established.
Use the lowest effective duration; reassess every 3 months: at 3-month intervals, reassess whether the targeted cognitive or longevity outcome is being met; if not, discontinue rather than escalate, to avoid open-ended exposure given the absence of long-term human safety data.
Discontinue immediately for serious symptoms: stop and seek medical evaluation for any new chest pain, syncope, severe headache, focal neurological deficit, persistent palpitations, or seizure, given the documented serious-adverse-event signal associated with the DMAE pathway.
Do not use during pregnancy planning, pregnancy, or breastfeeding: because of the in-vitro DMAE neural-tube-defect signal and the absence of human reproductive data, avoid use from preconception planning onwards.

Therapeutic Protocol

A standard practitioner-style centrophenoxine protocol used in older European geriatric practice and replicated in modern nootropic guides has the following structure:

Indication framing: centrophenoxine is most commonly used by health- and longevity-oriented adults with the goal of supporting age-related cognitive performance and reducing lipofuscin-related cellular aging, rather than for primary treatment of established neurological disease, which would belong to a clinician.
Standard daily dose range: 500–2,000 mg/day total. Healthy adults targeting cognitive support typically use 250–1,000 mg/day; older adults with subjective decline often use 750–1,500 mg/day; geriatric clinical trials in dementia have used 1,500–2,000 mg/day.
Dose schedule: twice-daily dosing (e.g., 500 mg morning + 500 mg early afternoon) is standard, reflecting an apparent 4–6-hour pharmacodynamic effect on alertness and short-term cognitive endpoints, with the longer-acting DMAE moiety supporting an underlying steady state.
Best time of day: with breakfast and the midday meal. The last dose should not be taken later than early afternoon to avoid sleep disruption.
Single-dose vs. split-dose: split dosing is preferred over once-daily because of the relatively short pharmacodynamic effect and to reduce peak-related adverse events such as restlessness or headache.
Half-life considerations: intact centrophenoxine is rapidly hydrolyzed; pharmacodynamic effect on alertness wanes over ~4–6 hours, while the DMAE metabolite has a longer apparent half-life (~24 hours), allowing some build-up over days.
Co-factor support: practical nootropic protocols frequently pair centrophenoxine with a balanced B-vitamin complex (B6, B9 (folate), B12) and dietary choline sources (egg yolk, liver, soy lecithin) to ensure substrate availability for choline–phospholipid pathways. Strong additional cholinergics (alpha-GPC, citicoline, huperzine A) are reserved for later, once tolerability is established.
Genetic considerations: individuals known to carry MTHFR C677T or A1298C variants associated with reduced enzyme activity should ensure adequate methylated-folate and B12 intake; APOE4 carriers should be aware that no centrophenoxine data demonstrate a specific cognitive benefit in this group, despite mechanistic interest.
Sex differences: efficacy and safety have not been formally stratified by sex; the limited transcriptomic data suggest a possibly stronger neuronal-gene-expression effect in females, while reproductive risk concerns specifically constrain use in women of child-bearing potential.
Age: use is most defensible in older adults (≥ 50–60 years) where preclinical and limited clinical signals concentrate; the rationale for chronic daily use in younger healthy adults is weaker and unsupported by direct evidence.
Baseline biomarkers: before starting, obtain blood pressure, heart rate, basic metabolic panel (creatinine, eGFR, electrolytes), liver enzymes, and a focused neurological history; in those over 60 or with cardiac risk, an ECG (electrocardiogram) is reasonable.
Pre-existing health conditions: mild controlled hypertension, mild cognitive impairment, and asymptomatic age-related forgetfulness are the conditions where the protocol is typically applied; severe cardiac, neurological, hepatic, renal, psychiatric, or reproductive conditions modify or preclude it as detailed above.

Where competing therapeutic approaches exist, the main alternatives presented without ranking are:

A conventional Western cognitive-aging approach centered on cholinesterase inhibitors (donepezil, rivastigmine, galantamine) for diagnosed dementia, with no role for centrophenoxine.
A continental European geriatric approach that has historically used meclofenoxate, piracetam, pyritinol, and nicergoline in mild-to-moderate dementia, often as monotherapy or in combinations such as Antagonic-Stress (developed by D. and S. Riga, who hold patents on the combination — a direct conflict of interest noted here as in section 2).
A functional/integrative longevity approach that frames centrophenoxine alongside choline donors (alpha-GPC, citicoline), antioxidants (vitamin E, glutathione precursors), and lifestyle interventions (sleep, exercise, fasting, nutrient density) as components of a broader cognitive-aging stack.

Discontinuation & Cycling

Lifelong vs. short-term: centrophenoxine is generally framed as either a finite trial (e.g., 3–6 months to assess response) or an ongoing intervention reassessed periodically. There is no human evidence to support open-ended lifelong use, and long-term safety data in healthy adults are sparse.
Withdrawal effects: no formal withdrawal syndrome has been described. Some users report a transient subjective “dip” in alertness for a few days after stopping, consistent with adjustment of the cholinergic and stimulant-type tone; objective rebound effects are not established.
Tapering protocol: because there is no documented physical dependence, abrupt cessation is generally tolerated. A practical taper for those on higher doses is to halve the dose for 3–7 days before stopping, primarily to monitor for any unmasking of underlying mood, sleep, or blood-pressure changes.
Cycling: several practitioner sources recommend 5-days-on / 2-days-off, or 8 weeks on / 2–4 weeks off, on the rationale of preventing tolerance to stimulant-type effects and limiting cumulative DMAE exposure. There is no controlled clinical evidence that cycling improves long-term efficacy; it is a precautionary heuristic rather than an evidence-based requirement.
Reassessment trigger: if no perceived benefit on the targeted cognitive or longevity outcomes is evident at 3 months, discontinuation is preferable to dose escalation, given the limited and heterogeneous human evidence base.

Sourcing and Quality

Regulatory status drives sourcing: centrophenoxine is an unapproved drug in the United States and is sold there as a “dietary supplement” despite that status; in Japan, China, Hungary, Germany, Austria, and several other countries it is a prescription medicine (e.g., Lucidril). Sourcing should be informed by the user’s jurisdiction and personal regulatory comfort.
Third-party testing is essential, not optional: in the 2022 Cohen et al. analysis, only 1 of 7 U.S. retail products contained a quantity within ±10% of label claim, so a current Certificate of Analysis (CoA) from an independent laboratory using HPLC (high-performance liquid chromatography) for identity and assay is the minimum acceptable evidence of product content.
Form and salt: the canonical form is centrophenoxine hydrochloride (meclofenoxate hydrochloride). Capsules of 250–300 mg are typical; bulk powder is also sold. Avoid undisclosed proprietary blends that obscure the centrophenoxine dose or pair it with stimulants.
Reputable suppliers: in Europe and Asia, prescription Lucidril or generic meclofenoxate from licensed pharmacies offers the highest assurance of identity and dose; in the U.S. supplement market, vendors that publish per-batch HPLC CoAs and operate under cGMP (current Good Manufacturing Practice, the FDA’s quality-system standards for manufacturing identity, strength, and purity)-registered facilities are the safest choice but still do not provide the assurance of a regulated drug.
Storage and shelf life: store sealed, away from heat and humidity; centrophenoxine, as an ester, is hygroscopic and vulnerable to hydrolysis in damp conditions. Discard products with visible discoloration or off-odor.

Practical Considerations

Time to effect: subjective cognitive effects (alertness, mental clarity) are commonly reported within 30–60 minutes of an oral dose; reproducible day-to-day cognitive effects are reported by users within 1–2 weeks; the lipofuscin-related preclinical effects develop over 8–12 weeks of continuous use; the 1977 healthy-elderly memory trial used a 9-month treatment period to detect a delayed-recall effect.
Common pitfalls: using a single late-day dose and disrupting sleep; stacking centrophenoxine on top of high-dose alpha-GPC or huperzine A and triggering cholinergic headache; trusting label values without third-party CoAs; using doses calibrated to dementia trials (1,500–2,000 mg/day) for general nootropic use without justification; treating animal lifespan data as established human evidence.
Regulatory status: in the United States, centrophenoxine is an unapproved drug and its sale as a “dietary supplement” is technically non-compliant; it is a prescription medicine in several countries and an in-competition prohibited stimulant under the WADA Prohibited List, which can have career consequences for tested athletes and military personnel.
Cost and accessibility: retail centrophenoxine in the United States costs roughly USD 0.20–0.50 per 250-mg capsule; Lucidril prescriptions in countries where it is approved range from comparable to modestly higher. The compound is broadly accessible online but rarely available through mainstream pharmacies in markets where it is unapproved.

Interaction with Foundational Habits

Sleep: centrophenoxine has a stimulant-type effect, and the most consistent tolerability complaint is insomnia or sleep fragmentation when the second dose is taken in the late afternoon or evening. Direction: blunting of sleep when mistimed; neutral to slightly supportive of daytime alertness when timed early. Practical: take the last dose by early afternoon (target ≤ 14:00 local time); avoid stacking with caffeine after midday during the first weeks.
Nutrition: centrophenoxine is taken with meals to reduce gastrointestinal upset and to provide co-factors for choline–phospholipid metabolism. Diets rich in choline (eggs, liver, soy lecithin), B-vitamins (B6, folate, B12), and omega-3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid)) support the same downstream pathways centrophenoxine depends on. Direction: potentiating in choline-replete states; possibly attenuated in low-choline diets. Practical: take with breakfast and lunch; ensure adequate dietary choline before adding additional cholinergic supplements.
Exercise: no direct interaction with strength or endurance adaptations is established. As a WADA in-competition prohibited stimulant, centrophenoxine is incompatible with tested competitive sport. Direction: neutral on hypertrophy or VO₂max (maximal rate of oxygen uptake during exercise, the standard measure of aerobic fitness) in non-tested settings; absolute incompatibility with WADA-tested in-competition use. Practical: time training away from peak centrophenoxine effect if it triggers restlessness; do not use within any in-competition window for tested athletes.
Stress management: anecdotal reports describe both calming (via improved cognitive control) and activating (via stimulant-type effects) responses; the underlying cholinergic activation may modestly support parasympathetic tone in some individuals, while DMAE’s stimulant component can heighten anxiety in others. Direction: variable, individual-dependent. Practical: pair the protocol with structured stress-reduction practices (sleep hygiene, breathwork, exercise) and monitor heart rate variability or subjective stress over the first 2–4 weeks; reduce dose if anxiety or palpitations emerge.

Monitoring Protocol & Defining Success

Baseline testing and ongoing monitoring focus on detecting the cardiovascular and neurological risks specific to centrophenoxine and on tracking the cognitive and aging-relevant outcomes that justify its use.

Baseline testing before starting includes office and home blood pressure measurement, resting heart rate, a basic metabolic panel (electrolytes, creatinine, eGFR), liver function tests, and, in those over 60 or with cardiac risk factors, an ECG; a brief standardized cognitive baseline (e.g., MoCA (Montreal Cognitive Assessment, a brief screen for cognitive impairment) or a structured digital cognitive battery) provides a meaningful before/after comparator.

Ongoing monitoring proceeds at 1 week (focused symptom check), 4 weeks (blood pressure, sleep, mood, cognitive subjective response), 12 weeks (full reassessment plus repeat cognitive testing), and then every 3–6 months for as long as the intervention continues.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Office and home blood pressure (systolic / diastolic)	Optimal: < 115 / 75 mmHg; Acceptable: < 130 / 80 mmHg	Detects stimulant-type hypertensive response early	Conventional “normal” upper limit is < 140/90 mmHg; functional medicine targets are tighter. Measure after 5 minutes seated; check at baseline, week 1–2, and at each dose increase
Resting heart rate	50–70 bpm	Tracks autonomic and stimulant load	Conventional normal range is 60–100 bpm; functional optimum is lower; measure on waking before caffeine
QTc interval (ECG)	< 440 ms (men) / < 460 ms (women); concerning > 500 ms	Screens for arrhythmic risk before stimulant-type exposure	Especially relevant in those > 60 years, with electrolyte disturbance, or on QT-prolonging drugs
eGFR	> 90 mL/min/1.73 m²	Assesses renal clearance for the DMAE pathway	Avoid if eGFR < 30; measure at baseline and annually
ALT / AST (liver enzymes)	ALT < 25 U/L (men), < 19 U/L (women); AST < 25 U/L	Confirms hepatic capacity for ester hydrolysis and DMAE handling	Conventional reference upper limit is ~ 40 U/L; functional optimum is lower
Fasting homocysteine	< 7 µmol/L	Reflects choline–methylation pathway adequacy	Conventional “normal” is < 15 µmol/L; functional optimum is < 7 µmol/L; high values suggest B-vitamin or choline insufficiency that may modify response
Standardized cognitive measure (e.g., MoCA total score)	Personal baseline; trend, not population norm	Tracks the targeted cognitive outcome	Use a fasting morning test, same time of day, away from peak centrophenoxine effect
Sleep quality (validated questionnaire or wearable-derived sleep efficiency)	Sleep efficiency > 85%; PSQI < 5	Detects the most common adverse effect (insomnia)	PSQI = Pittsburgh Sleep Quality Index, a validated 19-item self-report sleep questionnaire; best paired with a daily diary; assess at baseline and at week 4

Qualitative markers to track alongside the table:

Subjective mental clarity, focus duration, and ease of word retrieval
Sleep latency, mid-night awakenings, and morning refreshment
Mood stability (irritability, anxiety, low mood)
Headache or neck-tension frequency
Resting palpitations or chest discomfort (immediate stop trigger)
Self-reported energy across the day, especially mid-afternoon

Emerging Research

Hepatic encephalopathy combination trial: NCT03961087 is testing meclofenoxate plus coenzyme Q10 against standard care in hepatic encephalopathy (300 enrolled, NA (not applicable; the trial is not labeled with a conventional Phase 1–4 designation) phase, status: unknown / last update 2019). A positive outcome would extend centrophenoxine’s classical cognitive-rescue indication into a modern, biomarker-anchored hepatic-cognitive setting.
Repurposing for Parkinson’s disease: Zhang et al., 2025 used integrative multi-omics to propose meclofenoxate as a candidate Parkinson’s disease therapy, building on rotenone-model neuroprotection (Verma & Nehru, 2009) and α-synuclein anti-aggregation in vitro (Parui et al., 2023). These remain preclinical and would need formal human trials before clinical adoption.
Aging brain transcriptomics: Bakhtogarimov et al., 2022 showed that lifelong meclofenoxate in killifish partially reverses age-related neuronal-activity gene expression but does not blunt age-related inflammatory upregulation and may slightly increase certain senescence-associated transcripts, raising the question of whether long-term centrophenoxine is on balance pro- or anti-aging at the molecular level.
Senolytic and cholinesterase research: Darvesh et al., 2025 report differential senolytic inhibition of cholinesterases in Alzheimer-relevant contexts, a line of work that touches centrophenoxine’s mechanistic neighborhood and may eventually contextualize whether DMAE-derived choline support remains useful in the senolytic era.
Quality assurance and regulation: Cohen et al., 2022 and the broader Jędrejko et al., 2023 review continue to push for tighter post-market surveillance of nootropic supplements containing meclofenoxate; this regulatory direction could weaken the case for casual self-administration in the U.S. market while strengthening the case for prescription-grade product where available.

Conclusion

Centrophenoxine is a six-decade-old synthetic compound that delivers a choline-related molecule more efficiently into the aging brain. Its strongest signals are preclinical: reductions in lipofuscin, the brown waste pigment that builds up in old neurons; antioxidant effects in aged-rodent brain; and lifespan extension in older mouse studies that have not been replicated by modern controlled aging programs. Human evidence is comparatively thin and dominated by a single placebo-controlled memory trial in healthy elderly volunteers and small geriatric-psychiatry studies of mixed quality. Tolerability at typical doses is generally mild, but the active metabolite has a documented, if uncommon, signal of serious cardiac and neurological adverse events, and a contested reproductive safety profile.

For health- and longevity-oriented adults, centrophenoxine occupies an unusual position: long medical history in some countries, unapproved-drug status in others, modest and inconsistent cognitive evidence in humans, more interesting but unverified longevity signals in animals, and a supplement market in which most U.S. products are mislabeled. Much of the older clinical literature that frames it favorably also originates from the Riga group, who hold patents on the Antagonic-Stress combination — a direct conflict of interest that colors the evidence base. The current evidence supports treating centrophenoxine as an interesting but unproven longevity intervention rather than as an established one.

Top - Benefits - Risks - Protocol

Centrophenoxine for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Memory in Healthy Older Adults

Lipofuscin Reduction in Aged Brain Tissue ⚠️ Conflicted

Low 🟩

Antioxidant Marker Improvement in Aging Models

Cognitive Recovery After Acute Brain Insults

Lifespan Extension in Mice ⚠️ Conflicted

Speculative 🟨

α-Synuclein Anti-Aggregation and Parkinson’s-Relevant Effects

Senescence- and Choline-Pathway Modulation in Aging Brain

Skin and Cosmetic Effects

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Mild Stimulant-Type Adverse Events (Insomnia, Restlessness, Headache, Dizziness)

Medium 🟥 🟥

DMAE-Related Cardiac and Neurological Serious Adverse Events

Mood and Psychiatric Effects

Product-Quality and Mislabeling Risk

Low 🟥

Hypertension and Cardiovascular Risk in Susceptible Individuals

Seizure Threshold Lowering

Speculative 🟨

Reproductive and Developmental Toxicity

Long-Term Safety in Healthy Adults

Doping and Regulatory Sanction

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion